Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | PTAFR | P25105 | 8/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.38 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802205 | 0.90 | NAMPT (0.41) | NAMPTPTAFRHDAC8TBXAS1ACP1 | |
| SCHEMBL20777203 | 0.78 | NAMPT (0.51) | NAMPTPTAFRCNR1CNR2HDAC8 | |
| SCHEMBL22802202 | 0.78 | NAMPT (0.51) | NAMPTPTAFRCNR1CNR2HDAC8 | |
| SCHEMBL20777174 | 0.74 | GPR132 (0.51) | NAMPTPTAFRHDAC8TBXAS1 | |
| SCHEMBL22802207 | 0.74 | GPR132 (0.51) | NAMPTPTAFRHDAC8TBXAS1 | |
| SCHEMBL22802171 | 0.71 | CNR1 (0.48) | CNR1CNR2HDAC8 | |
| SCHEMBL22802212 | 0.67 | ROCK2 (0.44) | CNR1CNR2HDAC8 | |
| SCHEMBL15162082 | 0.67 | HDAC8 (0.56) | PTAFRCNR1CNR2HDAC8TBXAS1 | |
| SCHEMBL22802245 | 0.66 | CNR1 (0.45) | CNR1CNR2HDAC8 | |
| SCHEMBL22822686 | 0.64 | CNR1 (0.45) | CNR1CNR2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | PLEX PHARMACEUTICALS, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2021-12-23 | — | — | US | disclosed |
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | PLEX PHARMACEUTICALS, INC. | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399219-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885CNR1 3234/4885 |
| US-20210395203-A1 | DUAL ACTING FKBP12 AND FKBP52 INHIBITORS | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885CNR1 3234/4885 |
| US-12065407-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885CNR1 3234/4885 |
| US-12371406-B2 | Dual acting FKBP12 and FKBP52 inhibitors | FKBP2, FKBP1B, FKBP1A | NAMPT 2597/4885PTAFR 2518/4885CNR1 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.